Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094)
Conventional antidepressants increase the efflux of biogenic amine neurotransmitters (the monoamine hypothesis of depression) in the central nervous system (CNS) and are the principle drugs used to treat major depressive disorder (MDD). However, the lack of efficacy in some patients, the slow onset of action, and the side effect profiles of existing antidepressants necessitate the exploration of additional treatment options. The discovery of the nociceptin/orphanin FQ peptide NOP receptor (N/OFQ-NOP receptor) system and its characterization in preclinical biological and pharmacological stress-related conditions supports the potential antidepressant and anti-stress properties of a NOP receptor antagonist for the treatment of neurobehavioral disorders. BTRX-246040 (formerly LY2940094) was designed to test this hypothesis in the clinic. A small clinical proof of concept study demonstrated efficacy of BTRX-246040 in MDD patients. In this study, BTRX-246040 (40 mg, p.o.) significantly reduced negative bias as assessed by the facial recognition test within 1 week of treatment and decreased depression symptoms after 8 weeks. BTRX-246040 also reduced depression symptoms in a second trial with heavy alcohol drinkers. Given the comorbidity of MDD and alcohol use disorder, a compound with such effects in patients could be a valuable addition to the medications available. A proof of concept study showed efficacy of BTRX-246040 in reducing heavy drinking and increasing the probability of abstinence in individuals diagnosed with alcohol dependence. In addition, plasma levels of gamma-glutamyl transferase were decreased by BTRX-246040 compared to placebo control implying improvement in liver function. Collectively, the clinical data reviewed within this chapter suggest that BTRX-264040 functions to normalize dysfunction in reward circuits. The overall efficacy and safety of this compound with a novel mechanism of action are encouraging of further clinical development. BTRX-246040 is currently under development for MDD by BlackThorn Therapeutics.
KeywordsAlcohol use disorder Antidepressant BTRX-246040 LY2940094 Major depressive disorder N/OFQ NOP receptor antagonist Reward processing
Alcohol use disorder
- BTRX-246040 = LY2940094
Clinical Global Impression of Improvement
Clinical Global Impression of Illness Severity
Grid format of the Hamilton Depression Rating Scale, 17 items
Hospital Anxiety and Depression Scale
Hamilton Anxiety Rating Scale
Montgomery-Asberg Depression Rating Scale
Major depressive disorder
Maier-Philipp subscale of the GRID-HAMD-17
We thank the book editors for the invitation to review the data on BTRX-246040. JMW also thanks former colleagues with whom he had the pleasure and honor to work with in characterizing LY2940094 (now BTRX-246040). Specifically, he thanks Michael Statnick, Miguel Toledo, Linda Rorick-Kehn, Xia Li, Scott Gleason, Keith Wafford, and Vanessa Barth from Eli Lilly and Company (Indianapolis, Indiana, the USA, and Windlesham, Surrey, the UK), Roberto Ciccocioppo (University of Camerino, Italy), and John Pintar (Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA).
JMW dedicates this review to the memory of creative and energetic chemist, devoted humanitarian, and friend Conception Pedregal, who led the chemistry effort to discover BTRX-246040.
Conflict of Interest
WJM and TLW are employees of and shareholders in BlackThorn Therapeutics which is actively evaluating BTRX-246040 for the treatment of neurobehavioral disorders.
- Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61:807–816CrossRefGoogle Scholar
- Madrid A, Smith DG, Alvarez-Horine S, Saljooqi K, Dagum P, Mahableshwarkar A (2017) T122 assessing anhedonia with quantitative tasks and digital and patient reported measures in a multi-center, double-blind trial with BTRX-246040 for the treatment of major depressive disorder (NCT03193398). In American College of Neuropsychopharmacology 56th annual meeting, Palm SpringsGoogle Scholar
- Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F (2018) Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113(2):220–237CrossRefGoogle Scholar
- Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, Giovino GA, West R, Hall W, Griffiths P, Ali R, Gowing L, Marsden J, Ferrari AJ, Grebely J, Farrell M, Degenhardt L (2018) Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 113(10):1905–1926CrossRefGoogle Scholar
- Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM (2016b) A selective nociceptin receptor antagonist to treat depression: evidence from preclinical and clinical studies. Neuropsychopharmacology 41(10):1803–1812CrossRefGoogle Scholar
- Rorick-Kehn LM, Ciccocioppo R, Witkin JM, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Martínez-Grau M, Pedregal-Tercero C, Statnick MA (2016) A novel, orally-bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol-seeking in animal models. Alcoholism Clin Exp Res 40(5):945–954CrossRefGoogle Scholar
- Statnick MA, Chen Y, Ansonoff M, Witkin JM, Rorick-Kehn L, Suter TM, Song M, Hu C, Lafuente C, Jiménez A, Benito A, Diaz N, Martínez-Grau MA, Toledo MA, Pintar JE (2016) A novel nociceptin receptor antagonist LY2940094 inhibits excessive feeding behavior in rodents: a possible mechanism for the treatment of binge eating disorder. J Pharmacol Exp Ther 356(2):493–502CrossRefGoogle Scholar
- Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jiménez A, Benito A, Torrado A, Mateos C, Joshi EM, Kahl SD, Rash KS, Mudra DR, Barth VN, Shaw DB, McKinzie D, Witkin JM, Statnick MA, Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jiménez A, Benito A, Torrado A, Mateos C, Joshi EM, Kahl SD, Rash KS, Mudra DR, Barth VN, Shaw DB, McKinzie D, Witkin JM, Statnick MA (2014) Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7′-thieno[2,3-c]pyran) scaffold. J Med Chem 57(8):3418–3429CrossRefGoogle Scholar
- USDHHS (2015) Alcoholism: developing drugs for treatment – guidance for industry. Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM433618.pdf
- Vitale G, Filaferro M, Micioni Di Bonaventura MV, Ruggieri V, Cifani C, Guerrini R, Simonato M, Zucchini S (2017) Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. J Psychopharmacol 31(6):691–703CrossRefGoogle Scholar
- Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, Barth VN, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Martínez-Grau MA, Post A, Ansonoff MA, Pintar JE, Statnick MA (2016) Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacol Res Perspect 4(6):e00275CrossRefGoogle Scholar
- Zhang LL, Zheng HP, Ma C, He ZG, Zheng CD (2009) The plasma orphanin FQ in patients with depression before and after treatment. Chin J Psychiatry 42:138–144Google Scholar